Chiesi Group announced the operational launch of its biotech centre of excellence in Italy

Paul Healy, Director, PHARMeMED, shared a post on LinkedIn:

“Chiesi Group has announced the operational launch of its biotech centre of excellence in Italy.
The company has invested €400m to establish the facility, which it said is dedicated to developing and producing monoclonal antibodies, enzymes and other proteins.

Situated in Parma and set to employ up to 200 specialists, the site houses the entire supply chain in a single location, from the production of drug substances from mammalian cells to their transformation into drug products and final packaging.

This will be a “major advantage” and allow for more efficient transitions from development to manufacturing, Chiesi said, adding that the centre will support the production of small and large batches of both experimental and approved drugs.
The new site will also enhance the company’s focus areas of respiratory, special care treatments and rare diseases.

Alessandro Chiesi, Chiesi group chair, said: “[We have inaugurated] a centre with a production site that projects us into a new path of care, allowing us to continue making a difference in serving people and families living with chronic diseases, especially rare diseases, with increasingly innovative technologies.”

Of the approximately €400m investment, €120m has been allocated to infrastructure, while €260 million will be spent over the long term on materials, technologies, skills development and training.
Also commenting on the launch, Giuseppe Accogli, the company’s chief executive officer, said: “This centre will elevate our production capabilities to new heights and reinforce our dedication to driving innovation. More than that, it will empower us to forge powerful collaborations and push the boundaries of what’s possible in patient’s care.”

Read more.

Stay in touch with all the leading stories, events and opportunities by subscribing to my weekly LinkedIn Newsletter here.”

Source: Paul Healy/LinkedIn